1Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlates : Results of the Massachusset male aging study. J urol 1994 ; 151 : 54-6.
2Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States : Prevalence and predictors. JAMA 1999 ; 281 : 537-44.
3Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age : Results from the health professionals follow-up study. Ann Intern Med 2003 ; 139 : 161-8.
4Reynolds CF, Frank E, Thase ME, et al. Assessment of sexual function in depressed, impotent, and healthy men : Factor analysis of a brief sexual function questionnaire for men. Psychiatry Res 1988 ; 24 : 231-50.
5Morse JM. Erectile impotence precipitated by organic factors and perpetuated by performance anxiety. Can Med Assoc J 1982 ; 127 : 599-601.
6Lue T, Giuliano F, et al. Summary of the recommendations on sexual dysfunctions in men. JSM 2004 ; 1 : 6-23.
7 Guay AT, Spark RF, Bansal, S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction : A couple’s problem-2003 update. Endocr Pract 2003 ; 9 : 77-95.
8Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 1995 ; 45 : 498-502.
9 Ellenberg M. Impotence in diabetes : The neurologic factor. Ann Intern Med 1971 ; 75 : 213-9.
10Grover SA, Lowensteyn I, Kaouache M, et al. The prevalence of erectile dysfunction in the primary care setting : Importance of risk factors for diabetes and vascular disease. Arch Intern Med 2006 ; 166 : 213-9.
11 Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men : A randomized controlled trial. JAMA 2004 ; 291 : 2978-84.
12Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later : The Rancho Bernardo Study. J Am Coll Cardiol 2004 ; 43 : 1405-11.
13Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001 ; 87 : 838-45.
14Mannino DH, Klevens RM, Flaanders WD. Cigarette smoking : An independent risk factor for impotence ? Am J Epidemiol 1994 ; 140 : 1003. 166 : 213-17.
15Wein AJ, Van Arsdalen KN. Drug-induced male sexual dysfunction. Urol Clin North Am 1988 ; 15 : 20-31.
16Rüedi B, Magrini G. L’impuissance par dysfonction d’érection : intérêt mais limite des examens paracliniques et possibilités thérapeutiques. Med Hyg 1993 ; 51 : 312-4.
17 Leliefield HJ. Les troubles de l’érection : étiologie et diagnostic. Patient care 1992 ;43-54.
18Morgentaler A. Male impotence. Lancet 1999 ; 354 ; 1713-8.
19Levine SB, Rosenthal M. Marital sexual dysfunction : Female dysfunctions. Ann Intern Med 1977 ; 86 : 588-97.
20Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004 ; 172 : 290-4.
21McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride : A single-blind placebo controlled crossover study. J Urol 1998 ; 159 : 1935-8.
22Kara H, Aydin S, Yucel M, et al. The efficacy of fluoxetine in the treatment of premature ejaculation : A double-blind placebo controlled study. J Urol 1996 ; 156 : 1631-2.
23Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation : A double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994 ; 151 : 1377-9.
24Spark RF, White RA, Connolly PB. Impotence is not always psychogenic. Newer insights into hypothalamic-pituitary-gonadal dysfunction. JAMA 1980 ; 243 : 750-5.
25Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction : Clinical significance and cost-effective strategy. J Urol 1997 ; 158 : 1764-7.
26Earle CM, Stuckey BG. Biochemical screening in the assessment of erectile dysfunction : What tests decide future therapy ? Urology 2003 ; 62 : 727-31.
27Sohn MH. Current status of penile revascularisation for the treatment of male erectile dysfunction. J Androl 1994 ; 115 : 183-6.
28Mc Mahon et al. Treatment of erectile dysfunction with chronic dosing of Tadalafil. Eur Urol 2006 ; 50 : 215-7.
29Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil : Qualitative study. BMJ 2004 ; 328 : 1037.
30Fink HA, Mac Donald R, Rutks IR, et al. Sildenafil for male erectile dysfunction. A systematic review and meta-analysis. Arch Intern Med 2002 : 162 : 1349-60.
31Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002 ; 56 : 453-9.
32Burnett AL, Lowenstein CJ, Bredt D, et al. Nitric oxide synthase: A physiologic mediator of penile erection. Science 1992 ; 257 : 401-3.
33Jeremy JY, Ballard SA, Naylor AM, et al. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997 ; 79 : 958-63.
34Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983 ; 12 : 59-66.
35Benkert O, Witt W, Adam W, Leitz A. Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Arch Sex Behav 1979 ; 6 : 471-9.
36Aydin S, Odabas O, Ercan M, et al. Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. Br J Urol 1996 ; 77 : 256-60.
37Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandosterone in the treatment of erectile dysfunction : A prospective, double-blind randomized, placebo controlled study. Urology 1999 ; 53 : 590-4.
38Morales A, Johnston B, Heaton JW, Clark A. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1995 ; 152 : 1115-8.
39Knoll LD, Benson RC Jr, Bilhartz DL, et al. A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence. J Urol 1996 ; 155 : 144-6.
40De Boccard GA, Rochat CH. Prostaglandine E1- la prothèse pharmacologique. Ann Urol 1993 ; 27 : 152-5.
41Vobig MA, Klotz T, Staak M, et al. Retinal side-effects of sildenafil. Lancet 1999 ; 353 : 375.
42Garg RK, Khaishgi A, Dandona, P. Is management of impotence with sildenafil changing clinical practice ? Lancet 1999 ; 353 : 375-6.
43Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998 ; 338 : 1397-203.
44Schover LR, Fouladi RT, Warneke CL, et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002 ; 95 : 2397-407.
45Zippe LD, Kedia AW, Kedia K, et al. Treatment of erectile dysfunction after radical protatectomy with sildenafil citrate (Viagra). Urology 1998 ; 52 : 963-6.
46Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000 ; 86 : 57F-61.
47Pomara G, Morelli G, Pomara S, et al. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors : A study with sildenafil and vardenafil. J Androl 2004 ; 25 : 625-9.
48Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999 ; 99 : 168-77.
49Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005 ; 96 : 313-21.
50Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000 ; 36 : 25-31.
51Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004 ; 172 : 1935-40.
52Giuliano F, Hultling C, Masry E, et al. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Ann Neurol 1999 ; 1 : 15-21.
53Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes : A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999 ; 28 : 421-6.
54Montorsi F, McDermontt TE, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999 ; 53 : 1011-8.
55Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998 ; 338 : 1397-404.
56Borer J, Armstrong P; Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. Circulation 2003 ; 107 : e9052.
57Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients : A RigiScan and pharmacokinetic study. World J Urol 2001 ; 19 : 32-9.
58Hellstrom WJ, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction : results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003 ; 61 : 8-14.
59Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes : A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003 ; 26 : 777-83.
60Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction : Results of integrated analyses. J Urol 2002 ; 168 : 1332.
61Padma Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. MUSE study group. N Engl J Med 1997 ; 336 : 1-7.
62Wiliam G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE. Br J Urol 1998 ; 81 : 889-94.
63Govier FE, McClure RD, Weissman RM, et al. Experience with triple drug therapy in a pharmacologic erection program. J Urol 1993 ; 150 : 1822-4.
64Giuliano F, Blanchet P., Benoît G, Jardin A. Diagnostic et traitement de l’impuissance : indications des injections intracaverneuses. La presse médicale 1994 ; 23 : 1257-62.
65Linet OI, Ogrinc FG. Efficacy and safety of intracarvenosal alprostadil in men with erectile dysfunction. N Engl J Med 1996 ; 334 : 873-7.
66Kattan S, Collins JP, Mohr D. Double-blind, crossover srudy comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence. Urology 1991 ; 37 : 516-8.
67Tay KP, Lim PH. A prospective trial with vacuum assisted erection devices. Ann Acad Med Singapore 1995 ; 24 : 705-7.
68Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA 1983 ; 249 : 1736-40.
69Grimm RH, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997 ; 29 : 8-14.
70Smith DE, Wesson DR, Apter-Marsh M. Cocaine and alcohol induced sexual dysfunction in patients with addictive disorders. J Psychoactive Drugs 1984 ; 16 : 359.
71 Marceau L, Kleinman K, Goldstein I, et al. Does bicycling contribute to the risk of erectile dysfunction ? Results from the Massachusetts Male Aging Study (MMAS). Int J Impot Res 2001 ; 13 : 298-302.
72Sommer F, Schwarzer U, Klotz T, et al. Erectile dysfunction in cyclists. Is there any difference in penile blood flow during cycling in an upright versus a reclining position ? Eur Urol 2001 ; 39 : 720-3.
73Carter JN, Tyson JE, Tolis G, et al. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978 ; 299 : 847-52.
